Financial Architects (New Jersey)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Financial Architects (New Jersey)’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,500	Closed	-$5K	–	1637
2017 Q2	$5K	Hold	2,500	–	–	﹤0.01%	1303
2017 Q1	$10K	Hold	2,500	–	–	﹤0.01%	1148
2016 Q4	$12K	Hold	2,500	–	–	﹤0.01%	972
2016 Q3	$19K	Hold	2,500	–	–	0.01%	860
2016 Q2	$14K	Hold	2,500	–	–	﹤0.01%	890
2016 Q1	$13K	Buy	+2,500	New	+$14.5K	﹤0.01%	693

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Financial Architects (New Jersey)'s SRNE Position: Q3 2017 in Review

Financial Architects (New Jersey) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2017, closing a stake of 2,500 shares — an estimated $5K sold.

Financial Architects (New Jersey) first reported a position in SRNE in Q1 2016 and held it in 6 quarters. The position peaked at $19K in Q3 2016. 37 funds tracked by Wall St. Rank hold SRNE as of Q3 2017.

Financial Architects (New Jersey) reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Financial Architects (New Jersey) sold 2,500 Sorrento Therapeutics, Inc. shares in Q3 2017, an estimated $5K.
Financial Architects (New Jersey) first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
Financial Architects (New Jersey)'s Sorrento Therapeutics, Inc. position peaked at $19K in Q3 2016.
37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2017, filed 23 Oct 2017.